Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.50
Bid: 95.00
Ask: 102.00
Change: -2.50 (-2.48%)
Spread: 7.00 (7.368%)
Open: 101.00
High: 101.00
Low: 98.50
Prev. Close: 101.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans

Tue, 29th Aug 2023 10:23

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Pantheon Resources PLC, up 13% at 15.31p, 12-month range 10.10p-136.00p. The oil and gas company focused on onshore operations in the US receives independent expert report. It says the report provides an estimate of contingent resources recoverable from its 100% working interest Kodiak project, formerly known as Theta West. The company adds that the report confirms best estimate contingent resource estimates totalling 962 million barrels for Kodiak Field. Chief Executive Officer Jay Cheatham says: "This really is a big deal. A credible third-party estimate of nearly one billion barrels of recoverable liquids for a company the size of Pantheon is an incredible achievement, validating our geological model."

----------

Faron Pharmaceuticals Ltd, up 11% at 299.80p, 12-month range 155.00p-395.00p. The clinical-stage biopharmaceutical company says that the US Food & Drug Administration has granted orphan drug designation to its wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia. Orphan drug designation gives intellectual property cover and data protection to investigational drugs, as well as potential tax credits on eventual US sales of an approved orphan drug. Bexmarilimab is an immunotherapy designed to overcome resistance to existing treatments for acute myeloid leukaemia, a type of cancer, and myelodysplastic syndromes. "Receiving Orphan Drug Designation from the FDA signifies our continued progress and commitment to develop bexmarilimab as a potential treatment for AML," says Chief Medical Officer Marie-Louise Fjallskog. Also reports no revenue in the first half of 2023, unchanged year-on-year. Pretax loss widens to EUR13.7 million from EUR13.1 million.

----------

AIM - LOSERS

----------

Pelatro PLC, down 73% at 0.80p, 12-month range 0.69p-24.50p. The marketing software provider decides to cancel shares from AIM market in London, citing costs, management time required, and regulatory burden of maintaining a listing. It will announce schedule for the cancellation, including date of general meeting for shareholders to vote on the plan, "in due course". It will put in place a matched bargain facility to help shareholders buy and sell shares after the delisting. Nic Hellyer resigns as chief financial officer. Leaves board immediately but will remain with company to help with the share cancellation and financial reports. Pelatro says Bangalore-based finance function remains unaffected.

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
15 Jun 2020 12:44

Faron Pharmaceuticals gets Finnish state loan for manufacturing process

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced plans to initiate a new "state-of-the-art" process for the manufacturing of 'interferon' (IFN) beta-1a on Monday.

Read more
11 Jun 2020 13:51

Faron receives EIC grant for 'MATINS' study

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has been selected to receive a €2.5m (£2.24m) grant from the European Innovation Council's 'Accelerator' pilot scheme, it announced on Thursday, to progress the 'MATINS' study, and related business activities.

Read more
11 Jun 2020 13:23

UK TRADING UPDATE SUMMARY: Churchill China Sales Hit By Virus

UK TRADING UPDATE SUMMARY: Churchill China Sales Hit By Virus

Read more
20 May 2020 10:37

Faron Pharmaceuticals confirms publication of 'crucial' study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that the results of its detailed analyses into the effects of glucocorticoids on intravenous interferon beta-1a activity, which arose following the 'INTEREST' trial in 2018, had been published in critical care journal Intensive Care Medicine.

Read more
11 May 2020 16:48

Faron Pharma Gets EUR800,000 Grant From Finnish Cancer Consortium

Faron Pharma Gets EUR800,000 Grant From Finnish Cancer Consortium

Read more
11 May 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
5 May 2020 12:05

Faron Pharmaceuticals Picks Manufacturing Partner For Clevegen Therapy

Faron Pharmaceuticals Picks Manufacturing Partner For Clevegen Therapy

Read more
5 May 2020 09:20

Faron Pharmaceuticals inks manufacturing deal with AGC Biologics

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has selected contract development and manufacturing organisation AGC Biologics as the commercial-scale manufacturer of 'Clevegen', it announced on Tuesday.

Read more
27 Apr 2020 13:52

UK EXECUTIVE CHANGE SUMMARY: Corero Hires Former CML Finance Director

UK EXECUTIVE CHANGE SUMMARY: Corero Hires Former CML Finance Director

Read more
27 Apr 2020 13:51

UK TRADING UPDATE SUMMARY: Novacyt Called Upon To Ramp Up UK Testing

UK TRADING UPDATE SUMMARY: Novacyt Called Upon To Ramp Up UK Testing

Read more
22 Apr 2020 18:42

Faron Raises EUR14 Million In Oversubscribed Share Placing

Faron Raises EUR14 Million In Oversubscribed Share Placing

Read more
21 Apr 2020 18:21

Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million

Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million

Read more
1 Apr 2020 17:56

UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work

UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work

Read more
20 Mar 2020 11:25

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

Read more
20 Mar 2020 10:49

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.